Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 149

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 149
---
 |    ​ |      14,194 | ​ |
| Interest expense, promissory note            | ​ |                  ​ |    -536,138 | ​ |    ​ |    -596,018 | ​ |
| Total other income (expense)                 | ​ |                  ​ |   5,454,176 | ​ |    ​ |    -121,824 | ​ |
| Net loss before income taxes                 | ​ |                  $ |  -8,163,188 | ​ |    $ | -20,037,573 | ​ |
| Provision for income taxes                   | ​ |                  ​ |           — | ​ |    ​ |           — | ​ |
| Net loss                                     | ​ |                  $ |  -8,163,188 | ​ |    $ | -20,037,573 | ​ |

Net Sales Net sales for the year ended December 31, 2023, were $5,822,388, composed of $2,286,373 of net sales from Prescription Medicines and net sales of $3,536,015 from Medical Devices. Net sales for the year ended December 31, 2022, were $5,992,054, composed of $2,734,639 of net sales from Prescription Medicines and net sales of $3,257,415 from Medical Devices. For the year ended December 31, 2023, gross billings to customers representing 10% or more of the Company’s total gross billings included three customers that represented approximately 22%, 21%, and 17% of total gross billings. Gross billings is a non-GAAP financial measure. For a reconciliation of net sales to gross billings, see the section titled “Reconciliation of Non-GAAP Financial Measures” below. For the year ended December 31, 2022, gross billings to customers representing 10% or more of the Company’s total gross billings included four customers that represented approximately 26%, 21%, 17%, and 16% of total gross billings. Gross billings is a non-GAAP financial measure. For a reconciliation of net sales to gross billings, see the section titled “Reconciliation of Non-GAAP Financial Measures” below. Prescription Medicines sales consist of sales of Stendra® in the U.S. for the treatment of male ED. Stendra® is primarily sold directly to four main customers, as described above, which collectively accounted for approximately 92% of Stendra